Amylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AMLX
Amylyx Pharmaceuticals, Inc. (AMLX) Piotroski F-score
Amylyx Pharmaceuticals, Inc.'s Piotroski F-score for fiscal 2024 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 6 in fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 3 | (3.00) |
| FY2023 | 6 | 1.00 |
| FY2022 | 5 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (84.87%) | 10.84% | Fail | 0 |
| Positive operating cash flow | (167.65m) | 11.92m | Fail | 0 |
| Rising return on assets | (84.87%) | 10.84% | Fail | 0 |
| Cash flow above net income | 134.10m | (37.35m) | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 6.67 | 5.66 | Pass | 1 |
| No new shares issued | 68,142,200 | 67,234,000 | Fail | 0 |
| Rising gross margin | (42.65%) | 93.32% | Fail | 0 |
| Rising asset turnover | 0.25 | 0.84 | Fail | 0 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| SUPN Supernus Pharmaceuticals, Inc. compare | 5 |
| LQDA Liquidia Corporation compare | 5 |
| PBH Prestige Consumer Healthcare Inc. compare | 5 |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 4 |
| INDV Indivior Pharmaceuticals Inc. compare | 4 |
| PRGO Perrigo Company plc compare | 4 |
| AMLX Amylyx Pharmaceuticals, Inc. | 3 |
| ALVO Alvotech compare | 3 |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover